CD274 and cancer: Given the promising and durable clinical responses, the FDA approved three PD-1 antibodies, nivolumab, pembrolizumab, and cemiplimab, and three PD-L1 antibodies, atezolizumab, avelumab, and durvalumab, for multiple types of cancer in humans (4, 5).